Argollo MC, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S (2019) Interleukin-23 blockers: born to be first-line biologic agents in inflammatory bowel disease? Curr Pharm Des 25(1):25–31
Article CAS PubMed Google Scholar
Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B et al (2020) IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn’s disease. J Crohns Colitis 14(1):23–32
Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J et al (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381(13):1201–1214
Article CAS PubMed Google Scholar
Bishop C, Simon H, Suskind D, Lee D, Wahbeh G (2016) Ustekinumab in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr 63(3):348–351
Article CAS PubMed Google Scholar
Cameron FL, Garrick V, Russell RK (2016) Ustekinumab in treatment of refractory paediatric Crohn disease. J Pediatr Gastroenterol Nutr 62(3):e30
Article CAS PubMed Google Scholar
Rinawi F, Rosenbach Y, Assa A, Shamir R (2016) Ustekinumab for resistant pediatric Crohn disease. J Pediatr Gastroenterol Nutr 62(4):e34–e35
Fusillo SJ, Chang V, Stein RE, Maxwell EC, Conrad MA, Albenberg L et al (2018) 329 - Ustekinumab responders versus non-responders in refractory pediatric inflammatory bowel disease. Gastroenterology 154(6):S–82
Chavannes M, Martinez-Vinson C, Hart L, Kaniki N, Chao CY, Lawrence S et al (2019) Management of paediatric patients with medically refractory Crohn’s disease using ustekinumab: a multi-centred cohort study. J Crohns Colitis 13(5):578–584
Dayan JR, Dolinger M, Benkov K, Dunkin D, Jossen J, Lai J et al (2019) Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr 69(1):61–67
Article CAS PubMed PubMed Central Google Scholar
Do P, Andersen J, Patel A, Semrin G, Sifuentes-Dominguez L, Luu P et al (2021) Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn’s disease: a retrospective chart review. F1000Research 9:316
Article PubMed Central Google Scholar
Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC (2021) Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis 27(8):1210–1214
Kim FS, Patel PV, Stekol E, Ali S, Hamandi H, Heyman MB et al (2021) Experience using ustekinumab in pediatric patients with medically refractory Crohn disease. J Pediatr Gastroenterol Nutr 73(5):610–614
Article CAS PubMed PubMed Central Google Scholar
Koudsi M, Martinez-Vinson C, Pigneur B, Willot S, Djamal D, Enaud R et al (2023) Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the pediatric GETAID. J Pediatr Gastroenterol Nutr 76(6):763–770
Article CAS PubMed Google Scholar
Rosh JR, Turner D, Griffiths A, Cohen SA, Jacobstein D, Adedokun OJ et al (2021) Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: pharmacokinetics, safety, and efficacy results from UniStar, a Phase 1 study. J Crohns Colitis 15(11):1931–1942
Article PubMed PubMed Central Google Scholar
Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM et al (2021) STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160(5):1570–1583
Article CAS PubMed Google Scholar
Yerushalmy-Feler A, Pujol-Muncunill G, Martin-de-Carpi J, Kolho KL, Levine A, Olbjørn C et al (2022) Safety and potential efficacy of escalating dose of ustekinumab in pediatric Crohn disease (the speed-up study): a multicenter study from the Pediatric IBD Porto group of ESPGHAN. J Pediatr Gastroenterol Nutr 75(6):717–723
Article CAS PubMed Google Scholar
Takeuchi I, Arai K, Kyodo R, Sato T, Tokita K, Hirano Y et al (2021) Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children’s hospital in Japan. J Gastroenterol Hepatol 36(1):125–130
Article CAS PubMed Google Scholar
Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L et al (2014) ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58(6):795–806
Article CAS PubMed Google Scholar
Turner D, Levine A, Walters TD, Focht G, Otley A, Lopez VN et al (2017) Which PCDAI version best reflects intestinal inflammation in pediatric Crohn disease? J Pediatr Gastroenterol Nutr 64(2):254–260
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381
Van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL et al (2021) The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis 15(2):171–194
Fang S, Zhang S, Zhang C, Wang L (2023) Effectiveness and safety of ustekinumab for pediatric inflammatory bowel disease: a systematic review. Pediatr Drugs 25(5):499–513
Cohen A, Ahmed N, Sant’Anna A, (2021) Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience. Intest Res 19(2):217–24
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR et al (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375(20):1946–1960
Article CAS PubMed Google Scholar
Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N et al (2017) Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther 45(9):1232–1243
Article CAS PubMed Google Scholar
Harris KA, Horst S, Gadani A, Nohl A, Annis K, Duley C et al (2016) Patients with refractory Crohn’s disease successfully treated with ustekinumab. Inflamm Bowel Dis 22(2):397–401
Alric H, Amiot A, Kirchgesner J, Tréton X, Allez M, Bouhnik Y et al (2020) The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther 51(10):948–957
Article CAS PubMed Google Scholar
Greenup AJ, Rosenfeld G, Bressler B (2017) Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience. Scand J Gastroenterol 52(12):1354–1359
Article CAS PubMed Google Scholar
Penagini F, Lonoce L, Abbattista L, Silvera V, Rendo G, Cococcioni L et al (2023) Dual biological therapy and small molecules in pediatric inflammatory bowel disease. Pharmacol Res 196:106935
留言 (0)